Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESS: Relapse Risk After Glucocorticoid Withdrawal in Stable SLE
NCT02842814Completed
- Sponsor
- Peking Union Medical College Hospital
- Start
- Oct 2016
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of hydroxychloroquine in systemic lupus erythematosus (SLE) (3 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Percent of subjects with mild to moderate Lupus flare evaluated by modified SELENA-SLEDAI flare index (SFI) at 33 weeks. Started Oct 2016; status: completed.
02
Drugs
hydroxychloroquine
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02842814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842814.